Controlling Pharmaceutical Risks

The book delves into the evolution of drug testing since the late 1990s, focusing on the geneticization of carcinogenic risk assessment and pharmaceutical regulation. It explores critical issues in bio-science and medical treatment, questioning what knowledge is deemed essential for assessing carcinogenic risks to humans and examining the processes behind these judgments. Through this analysis, it highlights the implications for patient health and the complexities involved in pharmaceutical regulation.